Amin D, Richa T, Mollaee M, et al. - Using Visiopharm software in this retrospective analysis, researchers studied the impact of metformin on immune cell infiltrates of head and neck squamous cell carcinoma (HNSCC). Metformin was titrated to a standard diabetic dose (2000 mg/day) for at least 9 days before surgical resection (mean 13.6 days). From 36 individuals (16 HPV⁺, 20 HPV⁻), pre and posttreatment surgical specimens have been comparatively analyzed. Metformin treatment was linked to a 41.4% reduction in FOXP3⁺ T cells in intratumor regions of interest and a 66.5% rise in stromal CD8⁺ T cells at the leading edge of the tumor relative to pretreatment biopsies. This was expressed in increased CD8⁺/FOXP3⁺ cell ratios within the tumor and stromal compartments. Findings suggested that treatment with metformin could favorably alter the HNSCC immune tumor microenvironment regardless of HPV status.